louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02981589: Weaning Outcome From Invasive Mechanical Ventilation
Official title: Weaning Outcome From Invasive Mechanical Ventilation: a Prospective, Observational Cohort Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Patients Requiring Endotracheal Intubation and Invasive Mechanical Ventilation
Lead sponsor: Beijing Chao Yang Hospital
Sponsor class: OTHER
First posted: 2016-12-05
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients requiring endotracheal intubation and invasive mechanical ventilation

Brief summary: The main purpose of the present study was to explore the weaning failure rate from invasive mechanical ventilation and to identify risk factors of weaning failure.


Eligibility criteria: Inclusion Criteria:

* Requiring endotracheal intubation and invasive mechanical ventilation

Exclusion Criteria:

* Duration of invasive mechanical ventilation \< 48 hours；
* Presence of tracheostomy；
* Presence of upper airway obstruction.

Primary outcomes:
measure: Weaning failure rate
timeFrame: 3.5 years
measure: Spontaneous breathing trial failure rate
timeFrame: 3.5 years
measure: Extubation failure rate
timeFrame: 3.5 years
Secondary outcomes:
measure: ICU mortality
timeFrame: 3.5 years
measure: Hospital mortality
timeFrame: 3.5 years
measure: ICU length of stay
timeFrame: 3.5 years
measure: Hospital length of stay
timeFrame: 3.5 years
Other outcomes:
Locations:
city: Beiling
country: China
facility: Respiratory intensive care unit, Beijing Chao Yang Hospital Jingxi Campus
Study officials:
affiliation: Beijing Chao Yang Hospital
name: Zujin Luo, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Luo Z, Zheng Y, Yang L, Liu S, Zhu J, Zhao N, Pang B, Cao Z, Ma Y. Neutrophil/lymphocyte ratio is helpful for predicting weaning failure: a prospective, observational cohort study. J Thorac Dis. 2018 Sep;10(9):5232-5245. doi: 10.21037/jtd.2018.08.68.
Clinical trial NCT05650489: Autistic Features in Relation to Motor Function and Quality of Life in Children With an Autism Spectrum Disorder
Official title: Autistic Features in Relation to Motor Function and Quality of Life in Children With an Autism Spectrum Disorder
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Autism Spectrum Disorder
Keywords: Autism
Motor function
quality of life
autistic features
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-12-14
Enrollment: 40
Sex: ALL
Minimum age (years): 3
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Sample size calculation was performed using G power on the correlation between childhood autism rating scale and Quality of life for Spearman's rank correlation coefficient (rs) because it was the main outcome variable in the present study. a pilot study was performed on 5 patients and showed the correlation value was (r= 0.447226 and p\<0.001; and a large effect size (f= 0.447226). On the basis of the results of the pilot study (a minimum sample size of 34 patients was calculated. A sample size was increased to 34 patients, but the number will be increased to 40 to show appropriate results) a minimum sample size of 34 patients was calculated. A sample size was increased to 34 patients, but it was increased to 40 to show appropriate results.

Brief summary: Although motor limitations are not currently considered a as clinical manifestation of autism spectrum disorder, should not be ignored due to their high incidence and considerable influence on life quality functional activity


Eligibility criteria: Inclusion Criteria:

* Both sex,
* age ranges from 3 to 5 years,
* mild to moderate autistic features according to childhood autism rating scale ,
* were able to sit alone independently

Exclusion Criteria:

* Significant visual or auditory defects,
* history of cerebral palsy or psychiatric disorder (e.g attention deficit hyperactivity disorder)

Primary outcomes:
measure: Autism Index
timeFrame: baseline assessment
measure: Motor Development
timeFrame: baseline assessment
measure: Pediatric Quality of life Inventory Scale
timeFrame: baseline assessment
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Amira Mahmoud Abd-elmonem
Study officials:
affiliation: Cairo university, faculty of physical therapy
name: Eman s Albadry, B.S.C
role: PRINCIPAL_INVESTIGATOR
affiliation: Sohag University
name: Amr A OTHMAN
role: PRINCIPAL_INVESTIGATOR
affiliation: Cairo university, faculty of physical therapy
name: MAI E ABBASS
role: STUDY_CHAIR
References:
Clinical trial NCT01019889: Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection
Official title: Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Upper Respiratory Tract Infections
Keywords: upper respiratory tract infections
herbal medicine
Lead sponsor: Korea Health Industry Development Institute
Sponsor class: OTHER_GOV
First posted: 2009-11-25
Enrollment: 480
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether Socheongryong-tang (SCRT) and Yeongyopaedok-san (YPS) are effective in the treatment of upper respiratory tract infection.

Detailed description: Upper respiratory tract infections (URTIs) are the most prevalent disease of human beings, it incur a significant health burden on populations in terms of human suffering and economic losses. Usually, antibiotic therapy is not helpful since most infections are virally induced. Over 200 serologically different viral types are responsible for human URTIs, so that preventions of URTIs including vaccination are impassable. SCRT and YPS are widely used to treat the respiratory disease. The objective of this study is to determine the efficacy of SCRT and YPS in symptomatic relief of patients with URTIs.

Eligibility criteria: Inclusion Criteria:

* 18\~60 years old
* Clinical diagnosis of common cold
* Occurring no longer than 48 hours before enrollment
* Presented with runny nose, sore throat, plugged nose, scratchy throat, cough, hoarseness, headache, muscle ache (runny nose, sore throat and at least 1 of others or 1 of runny nose, sore throat and at least 3 of others)

Exclusion Criteria:

* Allergic rhinitis, asthma, COPD, sinusitis (2 and more recurrence per year), septal deviation, anatomical otitis media, exudative pharyngitis
* Received antihistamines, NSAIDs, corticosteroids, antibiotics, decongestants
* Hepatic cancer, liver cirrhosis, renal failure, congestive heart failure
* Pregnant or lactation

Primary outcomes:
measure: Changes of score daily measured by WURSS-K before, during and after treatment
timeFrame: daily (7 days)
Secondary outcomes:
measure: Time of symptom disappearance
timeFrame: daily
measure: Changes of score daily measured by WURSS-K before, during and after treatment in pattern identification
timeFrame: daily (7days)
Other outcomes:
Locations:
Study officials:
affiliation: Daejeon University
name: YangChun Park, Ph. D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02234089: Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Advanced Prostate Cancer
Lead sponsor: Ferring Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2014-09-09
Enrollment: 461
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with advanced prostate cancer where a treatment decision on therapy has already been made according to medical practice.

Brief summary: The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy (Degarelix or LHRH agonists).


Eligibility criteria: Inclusion Criteria:

* Diagnosed with Prostate Cancer and indicated for ADT according to Summary of Product Characteristics (SmPC)
* Decision made to prescribe ADT (Degarelix or LHRH agonist) prior to enrolment

Exclusion Criteria:

* Patient had previous or is currently under hormonal management of Prostate Cancer, except for a curative intention, where the duration of the neoadjuvant/adjuvant therapy did not exceed 6 months and treatment should have been terminated at least 6 months prior to baseline.
* Participation in a clinical trial at baseline and during the follow-up period

Primary outcomes:
measure: Level of urologist's knowledge of patients' medical history at the point of decision making and during Androgen Deprivation Therapy (ADT)
timeFrame: Up to 4 years
measure: Level of urologist's knowledge of patients' comorbidities at the point of decision making and during ADT
timeFrame: Up to 4 years
measure: Level of urologist's knowledge of patients' concomitant medications at the point of decision making and during ADT
timeFrame: Up to 4 years
measure: Level of urologist's knowledge of patients' risk factors at the point of decision making and during ADT
timeFrame: Up to 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: Rottweil
country: Germany
facility: Investigational site (there may be other sites in this country)
Study officials:
affiliation: Ferring Pharmaceuticals
name: Global Clinical Compliance
role: STUDY_DIRECTOR
References:
citation: Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Blumle A, Schmucker C, Mayer B, Kunath F. Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD012548. doi: 10.1002/14651858.CD012548.pub2.
Clinical trial NCT03519789: Cognitive and Emotional Factors in Visual Exploration Among Patients With Post-Traumatic Stress Disorder (SAILLANCE2)
Official title: Cognitive and Emotional Factors in Visual Exploration Among Patients With Post-Traumatic Stress Disorder
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Post-Traumatic Stress Disorder
Keywords: Change blindness
Eye tracking
Implicit response
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2018-05-09
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Thirty patients with PTSD and 30 participants exposed to trauma without PTSD will be asked to detect neutral or emotional changes in 96 scenes.

Brief summary: Post-traumatic stress disorder (PTSD) is characterized by hypervigilance. In particular, previous works suggest that patients tend to scan constantly the environment for possible threats. The present project aims at investigating such attentional bias in patients with PTSD using the change blindness paradigm that offers the interesting possibility of studying sensitivity to sudden changes using ecological stimuli. More precisely, the investigators will investigate whether patients are more sensitive than matched controls to sudden changes in the visual environment and whether this hypersensitivity is specific or even stronger when visual information has an emotional content. The attentional bias will be measured using motor responses (accuracy and speed to indicate the occurrence of a change by pressing a button) as well as eye movements.


Eligibility criteria: Inclusion Criteria:

* a diagnosis of PTSD based on the standard DSM-IV criteria,
* normal or corrected vision.
* clinically stable at the testing time

Exclusion Criteria:

* history of neurological illness or trauma that occurred in the previous six months, - pregnant and nursing women,
* drugs use in the last 24 hours,
* an acute ocular disorder.
* Participants will not be under tutorship, curatorship or deprived of liberty.

Primary outcomes:
measure: Response time before the detection of neutral and emotional stimuli.
timeFrame: Baseline: one session
Secondary outcomes:
measure: Number of correct detections compared with the missed detections and false alarms.
timeFrame: Baseline: one session
measure: Total duration until the participant first fixed on a ROI.
timeFrame: Baseline: one session
Other outcomes:
Locations:
city: Lille
country: France
facility: University Hospital, Lille
Study officials:
affiliation: University Hospital, Lille
name: Guillaume VAIVA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05725889: Detection of Visual-Auditory Reaction Rates in Individuals With Type 2 Diabetes
Official title: Detection of Visual-Auditory Reaction Rates in Individuals With Type 2 Diabetes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus, Type 2
Cognitive Dysfunction
Nerve Damage
Lead sponsor: Baskent University
Sponsor class: OTHER
First posted: 2023-02-13
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: The study population consisted of healthy individuals aged between 18-64 years, diagnosed with type 2 diabetes, and resided in Ankara. The sample comprised 128 volunteers, 64 of whom were patients and 64 were controls.

Brief summary: Background: The primary purpose of our study was to understand the damage in the peripheral nerves of patients with diabetes and to determine the change in patients' reaction rates and perceptions by the age groups, duration of diabetes, fasting plasma glucose and HbA1c values, and compare these with those of the healthy individuals.

Methods: This study was carried out at the Baskent University Hospital Endocrinology and Metabolic Diseases Outpatient Clinic. A total of 64 patients diagnosed with type 2 diabetes and 64 healthy controls were included in the study. Finger tapping, visual, and auditory reaction time tests were performed on the subjects, respectively. The subjects' fasting plasma glucose and HbA1c levels, and the duration of their diabetes were recorded. Analyses were performed using the SPSS version 25. Differences were considered statistically significant when the p-value is \<0.05.


Eligibility criteria: Inclusion Criteria:

* Right-handed individuals
* Must be between 18-65 ages
* Must be Type 2 diabetics at least 6 months (for patient group)

Exclusion Criteria:

* use of alcohol-drug or similar substances,
* the use of any medication that may affect neurological functions,
* having color blindness,
* retinopathy,
* neurological disease,
* cancer,
* depression,
* a recent history of surgery,
* rheumatoid arthritis,
* osteoarthritis,
* and advanced osteoarthritis.

Primary outcomes:
measure: Finger tap, visual and auditory reaction test data within 10 seconds
timeFrame: April-September 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Baskent University
Study officials:
affiliation: Baskent University
name: melisa bilaloğlu, res asst
role: STUDY_CHAIR
References:
Clinical trial NCT02340689: Primary Hyperoxaluria Mutation Genotyping/Phenotyping
Official title: Genetic Characterization and Genotype/Phenotype Correlations in Primary Hyperoxaluria
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Primary Hyperoxaluria
Keywords: PH
PH type 1
Primary Hyperoxaluria
Hyperoxaluria
Primary Oxalosis
PH type 2
PH type 3
Genetic testing for PH
Genetic testing for Primary Hyperoxaluria
Hereditary study for PH
Hereditary study for Primary Hyperoxaluria
AGXT
GRHPR
HOGA1
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2015-01-19
Enrollment: 1235
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: * Patients with clinical characteristics suggesting of primary hyperoxaluria
* Family members of patients with clinical characteristics suggestive of primary hyperoxaluria

Brief summary: Specific mutations relating to hyperoxaluria will be determined via DNA analysis by the Mayo RKSC research staff.

Detailed description: During your study visit, we will draw one tube, about two teaspoons (1 to 1 ½ teaspoons for children), of blood from your arm. White blood cells from the sample will be used as a source of DNA for genetic testing. We will use the DNA to try to identify mutations (changes) in one of the genes that can cause primary hyperoxaluria. This will be done by comparing it with the structure of these genes in normal individuals, patients with primary hyperoxaluria, and family members of primary hyperoxaluria patients. In family members of primary hyperoxaluria patients, a 24 hr urine test may also be collected.

Eligibility criteria: Inclusion Criteria:

* Ages birth to 99 years in whom clinical information is available from medical records
* Patients with a diagnosis of PH confirmed on previous genetic testing
* Patients with clinical suspicion of primary hyperoxaluria (elevated urine oxalate of greater than 0.8 mmol/1.73 m2/day (\>70 mg/1.73 m2/day), history of kidney stones, and/or nephrocalcinosis documented by medical history or imaging studies
* First or second degree family members of a patient with primary hyperoxaluria

Exclusion Criteria:

* Stone formers who do not have confirmed PH and do not meet the inclusion criteria for clinical suspicion of primary hyperoxaluria
* Unwilling or unable to provide consent/assent.

Primary outcomes:
measure: Genotype markers of early symptomatic onset of primary hyperoxaluria
timeFrame: 5 years
Secondary outcomes:
measure: Genotype markers of marked hyperoxaluria in patients with primary hyperoxaluria
timeFrame: 5 years
measure: Genotype markers of early loss of kidney function in patients with primary hyperoxaluria.
timeFrame: 5 years
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Dawn Milliner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04620889: LeMaitre LifeSpan® ePTFE Vascular Graft Retrospective Registry
Official title: A Retrospective Patient Registry on the Long-Term Safety and Performance of the LifeSpan® ePTFE Vascular Graft Used in Open Vascular Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diseased or Occluded Blood Vessels
Arteriovenous Shunting for Blood Access
Lead sponsor: LeMaitre Vascular
Sponsor class: INDUSTRY
First posted: 2020-11-09
Enrollment: 153
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This is a retrospective registry. The included population is therefore directly representative of the population in a real-world environment.

Brief summary: This is a post-market, single-arm, retrospective registry. The investigator or its representative will identify eligible patients through a medical record search.

Detailed description: This is a post-market, single-arm, retrospective registry. The investigator or its representative will identify eligible patients through a medical record search. Data will be captured retrospectively. Subjects will have been treated with the investigational device in the past and according to standard of care. Subjects will not be involved in any registry related procedures.

Eligibility criteria: Inclusion Criteria:

* Subject has undergone surgical treatment with the LifeSpan.
* Surgical treatment was for bypass or reconstruction of diseased or occluded blood vessels (PVP group) or arteriovenous shunting for blood access (AV group).
* For PVP group: Subject's surgical treatment was at minimum 3 years ago, and maximum 10 years ago, at time of enrollment.
* For AV group: Subject's surgical treatment was at minimum 2 years ago, and maximum 10 years ago, at time of enrollment.

Exclusion Criteria:

* None

Primary outcomes:
measure: Percentage of vessels patent without requiring intervention to remain open
timeFrame: 3 years
measure: Percentage of vessels patent without requiring intervention to remain open
timeFrame: 2 years
Secondary outcomes:
measure: Procedure type
timeFrame: Day of procedure
measure: Intra-operative technical success
timeFrame: Day of procedure
measure: Percentage of vessels patent without requiring intervention to remain open at 1 and 5 year primary patency
timeFrame: 1 year and 5 year
measure: Percentage of vessels patent with intervention to remain open at 1 and 5 year
timeFrame: 1 year and 5 year
measure: Percentage of vessels patent with intervention to remain open at 1 and 5 year for AV Access
timeFrame: 2 year
measure: Percentage of vessels patent with intervention to remain open at 1 and 5 year for PVP Group
timeFrame: 3 year
Other outcomes:
Locations:
city: Husum
country: Germany
facility: Klinikum Nordfriesland GmbH
Study officials:
References:
Clinical trial NCT06013189: Re-Adjustment of Sweep Gas Flow to the During the Rewarming Period of the Cardiopulmonary Bypass
Official title: Re-Adjustment of Sweep Gas Flow to the During the Rewarming Period of the Cardiopulmonary Bypass to Prevent Alkalosis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Optimal Sweep Gas Flow
Determination of Optimal Sweep Gas Flow for Different Phases of Cardiopulmonary Bypass
Keywords: sweep gas flow
rewarming
cardiopulmonary bypass
alkalosis
Lead sponsor: Acıbadem Atunizade Hospital
Sponsor class: OTHER
First posted: 2023-08-28
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients over 18 years of age scheduled for elective CPB surgery

Brief summary: The investigators designed this prospective observational study with the theory that alkalosis caused by decreased CO2 solubility due to temperature increase during the rewarming period of the Cardiopulmonary Bypass could be prevented by reducing the sweep gas flow during the rewarming period.


Eligibility criteria: Inclusion Criteria:

* Patients over 18 years of age
* Elective CPB surgery

Exclusion Criteria:

* Patients undergoing minimally invasive surgery
* Patients undergoing robotic cardiac surgery,
* Patients undergoing deep hypothermia,
* Patients undergoing total circulatory arrest,
* Patients whose FiO2 requirement is high that cannot be applied to target gas flow

Primary outcomes:
measure: Arterial pH lever lower than 7.30
timeFrame: during the cardiopulmonary bypass and postoperative 24th hour
Secondary outcomes:
measure: rSO2 20% below initial value
timeFrame: during the cardiopulmonary bypass
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Acıbadem Altunizade Hastanesi İstanbul
state: Altunizade
Study officials:
References: